Lion's Q3 Revenues Fall 65 Percent, Losses Narrow

Lion Bioscience last week reported sharply reduced revenues "in line with expectations," as well as reduced losses for its third fiscal quarter, ending Dec. 31, 2004.

Total revenues for the quarter fell 65 percent to €2.2 million ($2.9 million) from €6.3 million during the same period a year ago.

Lion did not break out its R&D costs for the quarter.

The company nearly halved its net loss for the quarter to €3.2 million from €6.3 million during the same quarter last year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.